Cytotoxic effects of a mixed ligand copper(II) chelate complex against a panel of human and murine cancer cells in vitro. Theoretical study of the mechanism of biologic action through molecular modelling.

Purpose: In an effort to discover new compounds with anticancer activity, we have developed a novel copper (II) [Cu(II)] chelate complex with a tridentate ONNSchiff base ligand and the anion of salicylate and we evaluated the in vitro chemosensitivity of various human and murine tumor cell lines by measuring cell growth inhibition. The ultimate goal was to evaluate the existence of a potential antitumor activity of this complex. Beyond the cytotoxic activity assessment of the complex, we aimed at the elucidation of the underlying mechanism of action of this complex and its interactions with biological molecules, carrying out theoretical (quantum-chemical) calculations.

Synergistic interaction between a novel mixed ligand copper(II) chelate complex and a panel of anticancer agents in T47D human breast cancer cells in vitro.

Purpose: We have developed a novel copper(II) chelate complex with a tridentate ONN-Schiff base ligand and the anion of salicylate, which presented a potent cytotoxic activity against a panel of human and murine cancer cell lines. In this experiment we explored the combined effect between Cu(SalNEt(2))salicylate (Cu-Sal) complex and the widely used anticancer drugs carboplatin (CBDCA), cyclophosphamide (CTX) and paclitaxel (TXL) against T47D human breast cancer cells. Theoretical (quantum-chemical) study of this complex and its adducts with biological molecules were carried out, aiming at the elucidation of the underlying mechanism of action.

Synergistic interaction between a mixed ligand copper (II) chelate complex and two anticancer agents in T47D human breast cancer cells in vitro.

Purpose: We have developed a copper(II) chelate complex with a tridentate ONN-Schiff ligand and the anion of salicylate, showing a potent cytotoxic activity against a panel of human and murine cancer cell lines. In this experiment we have explored the combination effect between Cu(SalNEt(2))salicylate (Cu-Sal) complex and two widely used drugs in cancer chemotherapy, bleomycin (BLM) and 5-fluorouracil (5-FU), against T47D human breast cancer cells. Previous theoretical quantum-chemical studies of this complex and ass adducts with biological molecules elucidated the underlying mechanism of action of this complex.

In vitro combined effect of a new series of copper (II) complexes with cisplatin or epirubicin on human breast and cervical cancer cell lines.

The in vitro cytotoxic effects of some recently synthesized copper (II) complexes were investigated in combination with two clinically important anticancer agents, cisplatin (CDDP) and epirubicin (EPR), on three human breast cancer cell lines (BT20, MCF7 and T47D), a human cervical carcinoma cell line (HeLa) and two non-tumour cell lines (BHK-21 and L929). The in vitro antiproliferative effects were measured by means of XTT assay and drug potency was expressed in terms of IC50 values. Synergistic effects were observed for EPR in combination with a Cu(II) malonate derivative in BT20, MCF7 and HeLa cells.

In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line.

The in vitro predictive chemosensitivity of a HeLa-S3 human cervical cancer cell line to a new series of Cu(II) complexes as well as their combination with several chemotherapeutic drugs was determined. Antiproliferative activity was evaluated by the XTT assay. Among all tested drugs, HeLa-S3 cells were especially sensitive to epirubicin (EPR) or mitomycin C (MMC) antitumor agents.